Li X, Xing S, Dong Q. Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature.
Oncotarget 2017;
8:55760-55765. [PMID:
28903458 PMCID:
PMC5589697 DOI:
10.18632/oncotarget.17406]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Accepted: 04/03/2017] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND
Solid tumors have a markedly decreased incidence in individuals with Down syndrome (DS), including lung cancers.
METHODS
The clinical presentation of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) in DS was reported and literature on the subject reviewed.
RESULTS
In individuals with DS, the risk of lung cancer appears markedly lower. EGFR mutation and EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance also exist in DS with lung cancer.
CONCLUSIONS
Clinicians should consider EGFR mutation and EGFR-TKIs resistance in lung cancer patients with DS.
Collapse